If you have a patient interested in volunteering to participate in a clinical research trial, please contact the Clinical Research office at (225) 215-1375, or by email at clinicalresearch@marybird.com.
Information on open clinical trials for bladder and urothelial cancers are below.
Title: A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (DDGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for those Patients whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
Purpose: This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer.
Patient Population:
| Clinical stage T2-T4aN0/xM0 disease. Histologically confirmed muscle-invasive urothelial carcinoma of the bladder. Urothelial carcinoma invading into the prostatic stroma with no histologic muscle invasion is allowed, provided the extent of disease is confirmed via imaging and/or examination under anesthesia (EUA). The diagnostic TURBT sample must have been obtained within 60 days prior to registration. 20 unstained slides (10 micron thickness) of formalin-fixed paraffin-embedded (FFPE) pre-treatment diagnostic transurethral resection (TUR) specimen available (for sequencing), with 2 (5 micron) slides at the start and end of the 20 slides, for a total of 22 unstained slides. An FFPE block is also acceptable. |
Offered in: Baton Rouge, Covington, Houma
Title: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozatinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGrEE]
Purpose: This phase III trial studies how well Nivolumab and Ipilimumab, followed by Nivolumab versus Cabozatinib and Nivolumab, work in treating patients with renal cell cancer that is untreated and has spread to other parts of the body.
Patient Population:
| Histologically documented renal cell carcinoma with clear cell component, including patients who have sarcomatoid features. Any metastatic disease, including visceral, lymph node, other soft tissue and bone, measurable per RECIST 1.1. Must be intermediate or poor risk patient per International Metastatic Renal Cell Carcinoma Database (IMDC) criteria (1 or more of the following: Karnofsky performance status [KPS] < 80, < 1 year from diagnosis [including initial nephrectomy] to systemic treatment for metastatic disease, hemoglobin less than lower limit of normal [LLN], corrected calcium concentration greater than upper limit of normal [ULN], absolute neutrophil count greater than ULN, platelet count > ULN). Central nervous system (CNS) disease permitted, if stable and not otherwise causing symptoms or needing active treatment. |
Offered in: Baton Rouge, Covington, Houma
Information on open clinical trials for brain cancers are below.
Title: A Pivotal Randomized, Open –Label Study of Optune (TTFIELDS, 200KHZ) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
Purpose: To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and Temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and Temozolomide alone. In both arms, Optune® and maintenance Temozolomide are continued following radiation therapy.
Patient Population:
| Histologically confirmed diagnosis of GBM according to WHO classification criteria. Age ≥ 22 years in US. Recovered from maximal debulking surgery, if applicable. Planned treatment with RT/TMZ followed by TTFields and maintenance TMZ (150-200 mg/m2 daily x 5 d, q28 days). |
Offered in: Baton Rouge – Neuromedical Center only
Information on open clinical trials for breast cancers are below.
Title: Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) For Low Risk DCIS: A Phase III Prospective Randomized Trial
Purpose: This study looks at the risks and benefits of active monitoring (AM) compared to surgery in the setting of a pragmatic prospective randomized trial for low risk DCIS.
Patient Population:
| Diagnosis of unilateral, bilateral, unifocal, multifocal, or multicentric DCIS without invasive breast cancer (date of diagnosis defined as the date of the first pathology report that diagnosed the patient with DCIS) OR: atypia verging on DCIS OR: DCIS + LCIS (mix and/or separate locations in the same breast). 40 years of age or older at time of DCIS diagnosis. ECOG performance status 0 or 1. No contraindication for surgery |
Offered in: Baton Rouge – Woman’s Hospital Only
Title: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Purpose: This phase III trial studies how well Carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body.
Patient Population:
| Women and men diagnosed with HER-2 positive metastic breast cancer who are at an increased risk of cardiotoxicity due to previous chemotherapy (anthracycline) exposure OR At least one risk factor for heart disease. Must be starting or continuing trastuzumab-based (Herceptin) HER-2 targeted therapy. |
Offered in: Baton Rouge
Title: Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
Purpose: This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.
Patient Population: Asymptomatic women age 40 and over scheduled for a screening mammogram and able to toleral digital breast tomosynthesis and full-field digial mammographic imaging. Cannot have symptoms of breast disease, new breast complaints, personal history of breast cancer or breast enhancements.
Offered in: Baton Rouge -Woman’s Hospital only
There are currently no active carcinoid clinical trials. Please check back as we are continuously opening new studies.
Information on open clinical trials for colorectal cancers are below.
Title: Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
Purpose: This phase II/III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery.
Patient Population:
| Patients treated with or without adjuvant chemotherapy following resection of stage IIA colon cancer |
Offered in: Baton Rouge
Title: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Purpose: This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer.
Patient Population:
| Stage II-III colorectal cancer patients scheduled to receive oxaliplatin 510 mg/m^2 (cumulative dose) over 12 weeks as a component of adjuvant leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin (FOLFOX) treatment, in which patients are scheduled to receive oxaliplatin 85 mg/m^2 every 2 weeks for 12 weeks (i.e., 6 cycles), or adjuvant capecitabine and oxaliplatin (CAPOX) treatment, in which patients are scheduled to receive oxaliplatin 135 mg/m^2 every 3 weeks for 12 weeks (i.e., 4 cycles) |
Offered in: Baton Rouge, Covington, Houma
Title: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer)
Purpose: This randomized phase III trial studies combination chemotherapy and Atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination chemotherapy, such as Oxaliplatin, Leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as Atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy with Atezolizumab may work better than combination chemotherapy alone in treating patients with colon cancer.
Patient Population:
| Histologically proven stage III colon adenocarcinoma (any T [Tx, T1, T2, T3, or T4], N1-2M0; includes N1C). Tumors must be deemed to originate in the colon including tumors that extend into/involve the small bowel (e.g. those at the ileocecal valve). DNA Mismatch Repair (MMR) Status: Presence of deficient (d) DNA mismatch repair (dMMR). MMR status must be assessed by immunohistochemistry (IHC) for MMR protein expression (MLH1, MSH2, MSH6, PMS2) where loss of one or more proteins indicates dMMR. dMMR may be determined either locally or by site-selected reference lab. |
Offered in: Baton Rouge, Covington, Houma
There are no current open clinical trials for Esophageal cancers. Please check back periodically as we are always adding new trials.
There are no current open clinical trials for GI cancers. Please check back periodically as we are always adding new trials.
Information on open clinical trials for GYN cancers are below.
Trial Number: MK-3475-A18/GOG-3047
Title: A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer(KEYNOTE-A18 / ENGOT-cx11)
Purpose: The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer.
Patient Population:
| Has high-risk locally advanced cervical cancer (LACC): The International Federation of Gynecology and Obstetrics (FIGO) 2014 Stage IB2-IIB (with node-positive disease) or FIGO 2014 Stages III-IVA. Has histologically-confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix |
Offered in: Covington – Women’s Cancer Care only
Title: A Phase III Randomized, Placebo – Controlled Study of Pembrolizumab (MK-3475, NSC #776864) IN Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVE or Recurrent Endometrial Cancer
Purpose: This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent).
Patient Population:
| Women with measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial cancer who have undergone institutional MMR IHC testing. |
Offered in: Baton Rouge (Breast & GYN Cancer Pavilion)
Title: A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma (FLORA-5)
Purpose: To compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of patients with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.
Patient Population:
| Newly diagnosed epithelial adenocarcinoma of ovarian, fallopian tube or peritoneal origin FIGO Stage III or IV disease. Histologic epithelial cell types: high grade serous adenocarcinoma, high grade endometrioid adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, or adenocarcinoma not otherwise specified (N.O.S.). |
Offered in: Covington – Women’s Cancer Care (Braly) only
Title: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (PROFECTA-II)
Purpose: Afuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum resistant ovarian cancer (PROC) progression. Afuresertib plus chemotherapy has demonstrated anti-tumor efficacy and an acceptable safety profile in patients with PROC in a published Phase I/II study. Therefore, the combination of afuresertib plus weekly paclitaxel could represent a clinically meaningful step forward in the clinical management of these difficult-to-treat patients with PROC.
Patient Population:
| Patients must have histologically or cytologically confirmed high grade serous OC, endometroid OC, or ovarian clear cell carcinoma (including fallopian tube and primary peritoneal cancers). Carcinosarcoma, sarcoma, mucinous OC, or low-grade serous OC or the other histologies must be excluded. Must have PROC (including fallopian tube and primary peritoneal carcinoma), defined as disease relapsed between 1 to 6 months after the last dose of the first-line platinum-based therapy (at least 3 cycles), or progressed during or relapsed within 6 months of the last dose of platinum-based 2nd-5th line therapies. |
Offered in: Covington – Women’s Cancer Care (Braly) only
Title: A phase II, single arm study of Mirvetuximab Soravtansine in recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression
Purpose: PICCOLO (IMGN853-0419) is a Phase 2 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Patient Population:
| Patients must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1. Patients must have a confirmed diagnosis of high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer. Patients must have platinum-sensitive disease defined as radiographic progression greater than 6 months from last dose of most recent platinum therapy Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression |
Offered in: Covington – Women’s Cancer Care (Braly) only
Trial Number: AVB500-OC-004/GOG-3059
Title: A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer. (AXLerate-OC)
Purpose: This is a randomize, double-blind Phase 3 study to compare the efficacy and safety of AVB-S6-500 in combination with paclitaxel (Pac) versus placebo in combination with Pac in patients with platinum resistant recurrent ovarian cancer.
Patient Population:
| Histologically confirmed and documented recurrent ovarian, fallopian tube, or peritoneal cancer. Only patients with high-grade serous adenocarcinoma histology are eligible. Platinum-resistant disease (defined as progression within ≤6 months from completion of most recent platinum-containing regimen and calculated from the date of the last administered dose of platinum therapy).Subject may have been treated with additional regimen(s) subsequent to determination of platinum resistance. |
Offered in: Covington – Women’s Cancer Care (Braly) only
Title:A Phase 2 Clinical Study of TJ004309 in Combination with Atezolizumab (TECENTRIQ(r)) in Patients with Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors.
Purpose: This is a multicenter, open label, Phase 2 study of TJ004309 in combination with atezolizumab in patients with advanced or metastatic solid tumors
Patient Population:
| This clinical study includes two cohorts: Cohort 1 will include Immuno-Oncology (IO) treatment naïve ovarian cancer (OC) patients who have progressed on or after platinum therapy; and Cohort 2 will include patients with head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), gastrointestinal cancer (GC), triple negative breast cancer (TNBC), or ovarian carcinoma (OC) with PD-L1 expression ≥ 1%. Additional cohorts for selected tumor types might be added later. |
Offered in: Covington – Women’s Cancer Care (Braly) only
There are no current open clinical trials for GI cancers. Please check back periodically as we are always adding new trials.
Information on open clinical trials for head and neck cancers are below.
Title:A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC
Purpose: This phase II/III trials studies whether maintenance immunotherapy (Nivolumab) following definitive treatment with radiation and chemotherapy (Cisplatin) result in significant improvement in overall survival (time being alive) and progression-free survival (time being alive without cancer) for patients with intermediate risk human papillomavirus (HPV) positive oropharynx cancer (throat cancer) that has spread to nearby tissue or lymph nodes.
Patient Population:
| Patients must have oropharynx cancer (American Joint Committee on Cancer [AJCC] 8) that is p16-positive by immunohistochemistry OR p16 equivocal by IHC and HPV positive by in situ hybridization with the following criteria: >= 10 pack-years, stage T1-2N2-N3 or T3-4N0-3 (less than 10 pack-years is considered a non-smoker) OR < 10 pack-years, stage T4N0-N3 or T1-3N2-3 |
Offered in: Baton Rouge
There are currently no active liver clinical trials. Please check back as we are continuously opening new studies.
Information on open clinical trials for lung cancers are below.
Title: A Randomized Phase III Trial od Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Purpose: This trial studies how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as Atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Patient Population:
| This trial is for men and women over the age of 18, with stage 1 or 2 non-small cell lung cancer. The cancer cannot have spread to lymph nodes or any other part of the body.Patient are at a higher risk for their cancer growing and spreading based on the size of their tumor, or other tumor features. Cannot or will not have lung cancer surgery. |
Offered in: Baton Rouge, Covington, Houma
Title: A Randomized Phase II Trial of Cabozantinib and Cabozantinib plus Nivolumab Versus Standard Chemotherapy in Patient with Previously Treated Non-Squamous NSCLC
Purpose: This phase II trial compares Cabozantinib alone and the combination of Cabozantinib and Nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung cancer (NSCLC). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Patient Population:
| Patient must have stage IV disease (includes M1a, M1b, or recurrent earlier stage disease). Patient must have predominant non-squamous histology (patients with NSCLC no otherwise specified [NOS] are eligible). Mixed tumors will be categorized by the predominant cell type. If small cell elements are present the patient is ineligible. |
Offered in: Baton Rouge, Covington, Houma
Title: Limited Stage Small Cell Lung Cancer (LS-SCLC): Phase II/III Randomized Study of Chemoradiation versus Chemoradiation Plus Atezolizumab
Purpose: This phase II/III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer.
Patient Population:
| Patients with pathologically (histologically or cytologically) proven diagnosis of limited stage (Tx, T1-T4, N0-3, M0) small cell lung cancer (LS-SCLC) who have received one pre-registration cycle of platinum/etoposide chemotherapy prior to study entry. |
Offered in: Baton Rouge, Covington, Houma
Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Purpose: This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient’s tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Patient Population:
| For pre-surgical patients: Suspected diagnosis of reseactabel NSCLC, suspected clinical stage of IIIA, II (A or B) or large IB (> 4 cm). For post-surgical patients: completely resected NSCLC with negative margis, pathologic stage IIIA, II (A or B)or large IB |
Offered in: Baton Rouge, Covington, and Houma.
Title: Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases from Small Cell Lung Cancer
Purpose: Determine whether stereotactic radiosurgery (SRS) relative to whole brain radiotherapy with hippocampal avoidance (HA-WBRT) plus memantine for brain metastases from small cell lung cancer (SCLC) prevents cognitive function failure as measured by cognitive decline on a battery of tests.
Patient Population:
| Small cell lung cancer within 5 years of registration |
Offered in: Baton Rouge, Covington, Houma
There are currently no open clinical trials for lymphoma cancers. Please check back as we are continuously opening new studies.
Information on open clinical trials for multiple sites/disease are below.
Title: Molecular Analysis for Therapy Choice (MATCH)
Purpose: This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients’ tumor cells.
Patient Population:
| Patients must have histologically documented solid tumors or histologically confirmed diagnosis of lymphoma or multiple myeloma requiring therapy and meet one of the following criteria: * progressed following at least one line of standard systemic therapy and there must not be other approval/standard therapy available that has been shown to prolong overall survival; if the patient is currently receiving therapy, the clinician must have assessed that the current therapy is no longer benefitting the patient prior to enrolling on MATCH OR * Patients for whose disease no standard treatment exists that has been shown to prolong overall survival * NOTE: No other prior malignancy is allowed except for the following: * Adequately treated basal cell or squamous cell skin cancer * In situ cervical cancer * Adequately treated stage I or II cancer from which the patient is currently in complete remission * Any other cancer from which the patient has been disease-free for 5 years |
Offered in: Baton Rouge, Covington, Houma
Trial Number: DCP-001
Title: Use of Clinical Trial Screening Selection Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program
Purpose: The objectives of this study are:
1) Implement a screening tool in NCORP to collect broader demographic and clinical data to generate hypothesis and research questions in the following areas of research: cancer screening, cancer prevention, symptom science, cancer care disparities, comparative effectiveness and cancer care delivery research.
2) Collect expanded demographic and clinical data (e.g., SES, co-morbidities, method of diagnosis) across the NCORP network to help identify and best characterize patients that are screened but not enrolled and for patients that participate in NCI trials, to understand how these variables may impact outcomes.
3) Enhance an understanding of site- specific and trial-specific accrual barriers that will inform the development of effective strategies to improve accrual, particularly for minority and underserved populations.
4) Provide data for internal and external evaluation of NCORP’s first RFA cycle and reissuance.
Offered in: Baton Rouge, Covington, and Houma.
Trial Number: URCC-21038
Title: Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
Purpose: This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood and saliva and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand health care disparities among all cancer patients.
Patient Population:
| Self-identify as African American or European American (Caucasian), have a current diagnosis of invasive cancer at stage I-IV and scheduled to receive anti-PD-1/L1 ICI containing therapy according to FDA labels or NCCN guidelines at Category 1 or 2A as standard of care treatment alone or in combination with co-treatments. |
Offered in: Baton Rouge, Covington, and Houma.
Trial Number: AZD7442 (EVUSHELD)
Title: Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2 Infection in Immuno-Suppressed Cancer Patients
Purpose: The Astra-Zeneca Immuno-Suppressed Program (AISP) is designed to address whether a patient treated for cancer who receives a single-dose of Evusheld (AZD7442) 600 mg IM or IV will maintain a stable/protective effect against symptomatic SARS-CoV-2 infection including SARS-CoV-2 related hospitalization and/or SARS-CoV-2 related death up to 12 months post-baseline.
Patient Population:
| Male or female, 18 years or older. Documented diagnosis of either hematologic malignancies or solid tumor as identified by standard ICD-10. Treatment much have been initiated less than or equal to 12 months prior to baseline for all patients. Must have received one or more doses of COVID-19 vaccine. |
Offered in: Baton Rouge
There are currently no active multiple myeloma clinical trials. Please check back as we are continuously opening new studies.
There are currently no open clinical trials for neuroendocrine cancers. Please check back as we are continuously opening new studies.
Information on open observational clinical trials are below.
Trial Number: S1912CD
Title: A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
Purpose: This clinical trial examines a financial navigation program in helping patients and their spouses understand and better manage the financial aspects of cancer care. Cancer patients and their spouses may be at high risk for financial problems because of the cost of cancer treatment.
Patient Population:
| Patients must have a diagnosis of a metastatic solid tumor or a hematologic malignancy and must receive anti-cancer treatment (i.e. chemotherapy, hormonal therapy, targeted therapy, biologic therapy, immune therapy, bone marrow transplant). Registration must occur within 120 days after diagnosis. Patients with indolent hematologic diseases undergoing observation alone are not eligible. Patients who have started anti-cancer treatment for the current diagnosis must have started within 60 days prior to registration |
Offered in: Baton Rouge, Covington, Houma
Information on our current Pancreatic cancer trials can be found below.
Title: A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment NaÏve Metastatic Pancreatic Cancer (GIANT)
Purpose: This phase II trial compares two treatment combinations: Gemcitabine Hydrochloride and Nab-Paclitaxel, or Fluorouracil, Leucovorin Calcium, and liposomal Irinotecan in older patients with pancreatic cancer that has spread to other places in the body (metastatic).
Patient Population:
| Newly diagnosed untreated metastatic adenocarcinoma of the pancreas. However, previous surgery, adjuvant chemotherapy and/or radiation therapy will be allowed, provided radiation therapy is completed at least 2 weeks prior to registration and adjuvant therapy was administered more than 6 months prior to registration. Patients with the following histology are excluded: acinar cell; adenosquamous carcinoma |
Offered in: Baton Rouge, Covington, Houma
Title: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Purpose: This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable).
Patient Population:
| Histologic or cytologic proof of pancreatic adenocarcinoma or adenosquamous carcinoma. TNM Stage: Tx-4, N0-1, M0 (M0 disease does not include spread to distant lymph nodes and organs). Determined to be appropriate candidate for curative-intent pancreatectomy by surgeon intending to perform the resection No prior radiation therapy, chemotherapy, targeted therapy, investigational therapy, or surgery for pancreatic cancer. |
Offered in: Baton Rouge, Covington, Houma
Title: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Purpose: This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Patient Population:
Patient must have a diagnosis of pancreatic cancer and have successfully undergone a curative intent surgical resection and must have no evidence of recurrent disease as determined by the investigator
Offered in: Baton Rouge
Trial Number:
Title:
Purpose:
Patient Population:
Offered in:
Information on open clinical trials for prostate cancers are below.
Title: Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)
Purpose: The objective of this study is to examine how adenocarcinoma of the prostate treatment differentially affects African American men’s ability to work and to describe and compare changes in work ability (as measured through self-reported global work ability item) reported by African American and white adenocarcinoma of the prostate survivors before treatment and 6 months after treatment completion.
Patient Population:
| Male diagnosed with adenocarcinoma of the prostate, stage I, II, or III. Patient may have already received hormonal therapy or expect to receive hormonal therapy as treatment for adenocarcinoma of the prostate. Scheduled to undergo prostatectomy or initiate radiation for primary curative treatment of adenocarcinoma of the prostate within 90 days of enrollment |
Offered in: Baton Rouge, Covington, Houma
There are currently no active renal clinical trials. Please check back as we are continuously opening new studies.
We do not have any currently open clinical trials for sarcoma cancers. Please check back as we are continuously adding new studies.
We do not currently have any open clinical trials for skin cancers. Please check back as we are continuously adding new studies.